Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

NCT ID: NCT06331624

Last Updated: 2025-10-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 35 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-04-24
• Study Completion Date: 2025-09-30

Brief Summary

This is a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study. Approximately 36 subjects with IPF will be randomized in a 2:1 ratio for GRI-0621 4.5mg or Placebo. GRI-0621 dose of 4.5mg will be compared with placebo following once daily oral administration for 12 weeks.

Concurrently, a Sub-Study will be conducted, examining the number and activity of NKT cells in BAL, for up to 12 eligible subjects (across various centers).

An early-stage patient variability assessment will be completed when 12 subjects have completed 2 weeks of treatment. Followed by an interim analysis performed when 24 subjects complete 6 weeks of treatment.

Conditions

Idiopathic Pulmonary Fibrosis; IPF

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

GRI-0621

GRI-0621 (tazarotene) 4.5mg, administered orally once daily (QD)

Group Type: EXPERIMENTAL

Tazarotene (GRI-0621)

Intervention Type: DRUG

Oral 4.5mg soft gel capsule

Placebo

Placebo 4.5mg, administered orally once daily (QD)

Group Type: EXPERIMENTAL

Placebo

Intervention Type: DRUG

Oral 4.5mg soft gel capsule

Interventions

Tazarotene (GRI-0621)

Oral 4.5mg soft gel capsule

Intervention Type: DRUG

Placebo

Oral 4.5mg soft gel capsule

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female subjects 40 through 85 years of age, inclusive.

2. Confirmed diagnosis of IPF with clinical features consistent with the current clinical practice guidelines for IPF.

3. FVC > 50% predicted value within 4 weeks of Screening.

4. FEV1/FVC ratio > 0.65 within 4 weeks of Screening.

5. Diffusion capacity for carbon monoxide corrected for hemoglobin (DLCOc) > 30%predicted value within 4 weeks of Screening.

6. Life expectancy of at least 12 months.

7. Willing and able to follow the study required visits and assessments. For Sub-Study subjects, willing and able to undergo BAL procedures at Screening and at Week 12.

8. Willing and able to provide written informed consent prior to study-related procedures.

Exclusion Criteria

1. Initiation of any approved or investigational IPF therapy or oral corticosteroids (> 10 mg/day) within 4 weeks of Screening. Subjects already on approved IPF therapies must remain on their current medication from Screening until the last study visit.

2. High resolution computerized tomography (HRCT) pattern showing emphysema more than the extent of fibrosis of the lung area within 12 months of Screening.

3. Acute exacerbation of IPF within 6 months of Screening (Collard et al., 2016).

4. Requiring supplemental O2 > 4 liters/min to maintain peripheral arterial O2 saturation (SpO2) > 88% at rest. O2 saturation at screening or baseline that is < 88% at rest.

5. Any condition with unacceptable risk for bronchoscopy (for Sub-Study subjects only).

6. Current or recent history of clinically significant medical condition, laboratory abnormality, or illness that could place the subject at risk or compromise the quality of the study data as determined by the Investigator.

7. Significant coronary artery disease (i.e., myocardial infarction within 6 months or unstable angina within 1 month of Screening).

8. An upper or lower respiratory tract infection, presence of or suspected emphysema, within 4 weeks of Screening.

9. Eye exam indicating night blindness within 6 months of Screening, or at Screening.

10. Bone Mineral Density t-score of -4.0 (severe osteoporosis) within 6 months of Screening, or at Screening.

11. Screening QT of >450 for men and >470 for women.

12. History of renal impairment as deemed clinically relevant by the investigator OR eGFR <60ml/min/1.73m2 within 60 days of Screening and a Screening eGFR of <60ml/min/1.73m2.

13. History of hepatic impairment as deemed clinically relevant by the investigator OR ALT or AST >2 x ULN OR moderate and severe hepatic impairment as defined using the Child-Pugh scoring system (i.e., Child-Pugh B and C).

14. A history of hypertriglyceridemia (documented TG of >2.0mmol/L at Screening); a history of pancreatitis from any cause; uncontrolled dyslipidemia with LDL-c >4.9mmol/L and an HDL-c <1.3 mmol/L for women and <1.0 for men, despite optimized treatment.

15. Use of moderate or strong inhibitors of CYP2C8 (e.g. gemfibrazol, trimethoprim, clopidogrel) or inducers of CYP2C8 (e.g. rifampin) from 7 days or 5 half-lives, whichever is longer, before the first administration of GRI-0621 until cessation of GRI-0621 administration.

16. Subjects who report any active suicidal ideation (SI) or behavior (SB) (i.e. Columbia Suicide Severity Rating Scale (C-SSRS) scores 4 or greater for SI and any positive scores for SB) during Screening or any past history thereof.

17. Current smoker (i.e., use of tobacco products within the last 3 months) of Screening.

18. Current or recent history of drug or alcohol abuse within 12 months of Screening.

19. Participation in any other investigational drug study within 4 weeks of Screening or within 5 times the elimination half-life of an investigational drug.

20. Females who are pregnant or breastfeeding, or if of child-bearing potential unwilling to practice two highly effective forms of contraception for at least 1 month prior to initiation of the study drug, during the study, and for 1 month after discontinuing the study drug (e.g., abstinence, intrauterine device or system, combination of barrier and spermicide, hormonal contraceptive, surgical sterilization, or male partner sterilization).

21. Males, if sexually active, unwilling to practice two highly effective forms of contraception during the study (e.g., condom, or surgical sterilization).

22. History of hypersensitivity or intolerance to oral tazarotene.

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

GRI Bio Operations, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Newport Native MD, Inc.

Newport Beach, California, United States

Mayo Clinic

Jacksonville, Florida, United States

Montefiore Medical Center

The Bronx, New York, United States

Southeastern Research Center

Winston-Salem, North Carolina, United States

MUSC Pulmonary Research

Charleston, South Carolina, United States

The Canberra Hospital

Garran, Australian Capital Territory, Australia

Concord General Repatriation Hospital

Concord, New South Wales, Australia

St. George Hospital

Kogarah, New South Wales, Australia

Royal Infirmary Edinburgh

Edinburgh, Scotland, United Kingdom

University Hospital Birmingham, Queen Elizabeth Hospital

Birmingham, , United Kingdom

Royal Papworth Hospital NHS Foundation Trust

Cambridge, , United Kingdom

Royal Devon and University Healthcare NHS Foundation Trust

Exeter, , United Kingdom

University College London Hospitals

London, , United Kingdom

Western Health and Social Care Trust (WHSCT)

Londonderry, , United Kingdom

Norfolk & Norwich University Hospital

Norwich, , United Kingdom

Oxford University Hospitals NHS Foundation Trust

Oxford, , United Kingdom

Countries

United States; Australia; United Kingdom

Other Identifiers

GRI-0621-IPF-02

Identifier Type: -

Identifier Source: org_study_id